Publication | Open Access

Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: A Gynecologic Oncology Group study

Phase Ii TrialMedicineMetronomic TherapyGynecologyTumor BiomarkersMtor InhibitorMetronomic ChemotherapyCancer TreatmentOncologyRadiation OncologyGynecology OncologyOvarian Cancer